PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Critical Care Medicine, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.\', \'Department of Critical Care Medicine, Zhejiang Hospital, Hangzhou, China.\', \'Department of Surgical Intensive Care Unit, Huadong Hospital Affiliated to Fudan University, Shanghai, China.\', \'Intensive Care Unit, Huangshi Central Hospital, Affiliated Hospital of Hubei Polytechnic University, Huangshi, China.\', \'Department of Critical Care Medicine, Wuhan No.9 Hospital, Wuhan, China.\', \'Tuberculosis and Respiratory Department, Wuhan Jinyintan Hospital, Wuhan, China.\', \'Intensive Care Unit, Huazhong University of Science and Technology Union Jiangbei Hospital, Wuhan, China.\', \'Intensive Care Unit, Tianyou Hospital Affiliated to Wuhan University of Science & Technology, Wuhan, China.\', \'Service de Médecine-Intensive Réanimation, Hôpital Bicêtre, AP-HP. Université Paris-Saclay, Inserm UMR 999, Université Paris-Saclay, Le Kremlin-Bicêtre, France.\', \'Department of Intensive Care, Hôpital Raymond Poincaré (APHP), Laboratory of Infection & Inflammation - U1173, School of Medicine Simone Veil, University Versailles Saint Quentin - University Paris Saclay, INSERM, Garches, France.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.3389/fimmu.2021.673693
?:hasPublicationType
?:journal
  • Frontiers in immunology
is ?:pmid of
?:pmid
?:pmid
  • 34408744
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 2.803
?:rankingScore_hIndex
  • 69
?:title
  • Efficacy of Thymosin Alpha 1 in the Treatment of COVID-19: A Multicenter Cohort Study.
?:type
?:year
  • 2021

Metadata

Anon_0  
expand all